

SC42025 FILTERING AND IDENTIFICATION

TURBULENCE MODELING FOR ADAPTIVE OPTICS

Aniket Ashwin Samant, Snehal Jauhri
(Student IDs: 4838866, 4772202)

January 13, 2019

Contents

References	8
----------------------	---

INTRODUCTION

This assignment deals with modeling an *Adaptive Optics* (AO) system in which three different data-driven turbulence modeling methods are used to achieve optimal control performances, viz.

- a random-walk process
- a Vector-Auto-Regressive model
- a stochastic state-space model

Each model has some questions associated with it, and we solve them in chronological sequence taking one model at a time.

1. RANDOM WALK MODEL

Question 1

We know from the assignment's equation (2) that:

$$s_o(k) = G\phi(k) + e(k)$$

We have the values of the wavefront sensor data in open-loop, $s_o(k)$, and also the value of the matrix G . To compute the value of $\hat{\phi}(k)$, given no prior information on it, we follow the linear least-squares approach:

First, we determine whether the matrix G is full-rank or not. We load the *systemMatrices.mat* file which contains the matrix G , and then run the *rank* command in MATLAB to get a rank value of **47**, which is less than $\min(\text{number of rows}, \text{number of columns})$ of G . Thus, we need to employ a linear least-squares method that doesn't assume the matrix G to be full-rank.

We know that there are multiple solutions to this problem, and for uniqueness we go with one such that the optimal solution, $\hat{\phi}(k)$, has a minimal 2-norm, thus leading to the original linear least-squares problem being reformulated as:

$$\min_{\phi(k) \in \Gamma} \|\phi(k)\|_2^2 \text{ with } \Gamma = \left\{ \phi(k) : \phi(k) = \arg \min_z \|Gz - s_o(k)\|_2^2 \right\}$$

By performing an SVD operation on the matrix G , we obtain:

$$G = \begin{bmatrix} U_1 & U_2 \end{bmatrix} \begin{bmatrix} \Sigma & 0 \\ 0 & 0 \end{bmatrix} \begin{bmatrix} V_1^T \\ V_2^T \end{bmatrix} = U_1 \Sigma V_1^T$$

Here, $\Sigma \in \mathbb{R}^{47 \times 47}$ is non-singular, by the definition of SVD.

Now, let us define a partitioned vector,

$$\begin{bmatrix} \xi_1 \\ \xi_2 \end{bmatrix} = \begin{bmatrix} V_1^T \\ V_2^T \end{bmatrix} z$$

Thus, our problem becomes:

$$\min_{\xi_1} \|U_1 \Sigma \xi_1 z - s_o(k)\|_2^2$$

We get $\hat{\xi}_1 = \Sigma^{-1} U_1^T s_o(k)$, since Σ is a non-singular matrix. ξ_2 has no effect on the above expression and can be chosen arbitrarily. Thus, we get the optimal solution,

$$\hat{z} = \begin{bmatrix} V_1 & V_2 \end{bmatrix} \begin{bmatrix} \hat{\xi}_1 \\ \hat{\xi}_2 \end{bmatrix} = V_1 \Sigma^{-1} U_1^T s_o(k) + V_2 \hat{\xi}_2$$

Since we're choosing a vector $\phi(k)$ with the smallest 2-norm, and $V_1^T V_2 = 0$ we get:

$$\|\phi(k)\|_2^2 = \|V_1 \Sigma^{-1} U_1^T s_o(k)\|_2^2 + \|V_2 \hat{\xi}_2\|_2^2$$

As we're minimizing the norm, we take $\hat{\xi}_2 = 0$ and we finally get the value of $\hat{\phi}(k)$ to be:

$$\hat{\phi}(k) = V_1 \Sigma^{-1} U_1^T s_o(k)$$

Question 2

We are provided with some prior information about the wavefront, viz.:

- $E[\phi(k)] = 0$
- $E[\phi(k)\phi(k)^T] = C_\phi(0)$
- noise variance = σ_e^2

Based on equation (8) from the assignment, we approximate the value of $C_\phi(0)$ as:

$$C_\phi(0) = \frac{1}{N} \sum_{i=1}^N \phi(i)\phi(i)^T \quad (1)$$

We have the data necessary to formulate our problem of determining $\phi(k)$ as a stochastic linear least-squares problem, and hence we define our linear estimator $\tilde{\phi}(k)$ accordingly:

$$\tilde{\phi}(k) = \begin{bmatrix} M & N \end{bmatrix} \begin{bmatrix} s_o(k) \\ E[\phi(k)] \end{bmatrix}$$

such that $E[(\tilde{\phi}(k) - \phi(k))(\tilde{\phi}(k) - \phi(k))^T]$ is minimized and $E[\tilde{\phi}(k)] = E[\phi(k)] = 0$

Thus, from the assignment's equation (2), based on $s_o(k)$'s expression, we can say,

$$\tilde{\phi}(k) = MG\phi(k) + Me(k) + NE[\phi(k)]$$

Since $E[\tilde{\phi}(k)] = E[\phi(k)] = 0$, we have:

$$\tilde{\phi}(k) = MG\phi(k) + Me(k)$$

Furthermore,

$$\phi(k) - \tilde{\phi}(k) = (I - MG)\phi(k) - Me(k)$$

Thus, the covariance of the above expression is computed as:

$$E[(\phi(k) - \tilde{\phi}(k))(\phi(k) - \tilde{\phi}(k))^T] = E[(I - MG)\phi(k) - Me(k))(I - MG)\phi(k) - Me(k))^T]$$

On expanding the right side of the equation and taking the error $e(k)$ to be uncorrelated with the wavefront vector $\phi(k)$, and based on the statistical data provided to us, we get the following expression:

$$E[(\phi(k) - \tilde{\phi}(k))(\phi(k) - \tilde{\phi}(k))^T] = (I - MG)C_\phi(0)(I - MG)^T + M\sigma_e^2 I M^T$$

On further factorization, using the Schur complement of the factorized version, and the application of the "completion of squares" argument to the resulting equation, we get the optimum value of the matrix M that minimizes the covariance expression as:

$$M = C_\phi(0)G^T(GC_\phi(0)G^T + \sigma_e^2 I)^{-1}$$

(A point to note here: the term in brackets is invertible since $C_\phi(0)$ is a positive definite matrix and $\sigma^2 I$ is non-singular)

Accordingly, we also get the optimum estimate of the wavefront vector,

$$\hat{\phi}(k|k) = C_\phi(0)G^T(GC_\phi(0)G^T + \sigma_e^2 I)^{-1}s_o(k)$$

For questions 3 to 5, we assume $E[\epsilon(k)] = 0$ and $E[\epsilon(k)\epsilon(k)^T] = C_\phi(0)$

Question 3

Now, we consider the closed-loop system, and proceed to derive a UMVE of $\epsilon(k)$ using the given measurement set $s(k)$. As in the previous question, we are provided with some prior information about the wavefront, viz.:

- $E[\epsilon(k)] = 0$
- $E[\epsilon(k)\epsilon(k)^T] = C_\phi(0)$
- noise variance = σ_e^2

We can clearly see that the equations (2) and (5) in the given assignment are similar, and we are told that the statistical data (the wavefront's and noise's mean and covariance values) are the same. Hence, as in the previous question, the optimum estimate of the wavefront vector is quite similar in the closed-loop system, and the only difference is in the value of the output vector, which in this case will be the closed-loop slope vector $s(k)$:

$$\hat{\epsilon}(k|k) = C_\phi(0)G^T(GC_\phi(0)G^T + \sigma_e^2I)^{-1}s(k)$$

Question 4

In this question, we make use of the random walk model represented by equation (9) in the assignment.

We know that:

$$\begin{aligned}\epsilon(k) &= \phi(k) - Hu(k-1) \\ \implies \phi(k) &= \epsilon(k) + Hu(k-1) \\ \implies \phi(k+1) &= \epsilon(k+1) + Hu(k)\end{aligned}$$

From the random walk model, we can relate $\phi(k)$ and $\phi(k+1)$, and substituting the above expressions respectively yields:

$$\epsilon(k+1) + Hu(k) = \epsilon(k) + Hu(k-1) + \eta(k)$$

If we consider $\hat{\epsilon}(k|k)$ to be the current optimal estimate, we know that the optimal one-step ahead prediction should not be stochastic in nature, and must be estimated based on the current optimal estimate. Based on the above equation, we can thus say,

$$\hat{\epsilon}(k+1|k) = \hat{\epsilon}(k) + Hu(k-1) - Hu(k)$$

Question 5

Find Optimal Increment.

2. VAR MODEL

Question 1

We know from the assignment's equation (2) that:

$$s_o(k) = G\phi(k) + e(k)$$

We have the values of the wavefront sensor data in open-loop, $s_o(k)$, and also the value of the matrix G . To compute the value of $\phi(k)$, given no prior information on it, we follow the linear least-squares approach:

content...

Question 2

We are provided with some prior information about the wavefront, viz.:

- $E[\phi(k)] = 0$
- $E[\phi(k)\phi(k)^T] = C_\phi(0)$
- noise variance = σ_e^2

Based on equation (8) from the assignment, we approximate the value of $C_\phi(0)$ as:

$$C_\phi(0) = \frac{1}{N} \sum_{i=1}^N \phi(i)\phi(i)^T$$

WE HAVE THE REQUIRED DATA NOW WE JUST NEED TO COMPUTE THE EXPRESSIONS. Pg 113 in book

For questions 3 to 5, we assume $E[\epsilon(k)] = 0$ and $E[\epsilon(k)\epsilon(k)^T] = C_\epsilon(0)$

Question 3

Similar to previous question but with now closed loop expression for $s(k)$.

Question 4

Use an expression similar to Kalman Gain to get ideal predictor.

Question 5

Find Optimal Increment.

REFERENCES

Anand, U., 2010. The Elusive Free Radicals, *The Clinical Chemist*, [e-journal] Available at:<<http://www.clinchem.org/content/56/10/1649.full.pdf>> [Accessed 2 November 2013]

Biology Forums, 2012. *Normal glomerulus. Acute glomerulonephritis*. [online] Available at: <<http://biology-forums.com/index.php?action=gallery;sa=view;id=9284>> [Accessed 23 October 2013].

Budisavljevic, M., Hodge, L., Barber, K., Fulmer, J., Durazo-Arvizu, R., Self, S., Kuhlmann, M., Raymond, J. and Greene, E., 2003. Oxidative stress in the pathogenesis of experimental mesangial proliferative glomerulonephritis, *American Journal of Physiology - Renal Physiology*, 285(6), pp. 1138-1148.

Chien, C., Lee, P., Chen, C., Ma, M., Lai, M. and Hsu, S., 2001. De Novo Demonstration and Co-localization of Free-Radical Production and Apoptosis Formation in Rat Kidney Subjected to Ischemia/Reperfusion, *Journal of the American Society of Nephrology*, 12(5), pp. 973-982.

Couser, W., 1993. Pathogenesis of glomerulonephritis, *Kidney International Supplements*, 42, pp. 19-26.

De Gasparo, M., 2002. Angiotensin II and nitric oxide interaction, *Heart Failure Reviews*, [e-journal] Available at:<<http://www.ncbi.nlm.nih.gov/pubmed/12379820>> [Accessed 26 October 2013]

Edinburgh Renal Education Pages, 2012. *Glomerulonephritis* [online] Available at: <<http://www.edrep.org/pages/textbook/glomerulonephritis.php>> [Accessed 25 October 2013].

Forbes, J., Coughlan, M. and Cooper, M., 2008. Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes, *Diabetes*, 57(6), pp. 1446-1454.

Geeky Medics, 2010. *Glomerulonephritis* [online] Available at: <<http://geekymedics.com/2010/10/27/glomerulonephritis/>> [Accessed 25 October 2013].

Gryglewski, R., Palmer, R., Moncada, S., 1986. Superoxide anion is involved in the breakdown of endothelium derived relaxing factor, *Nature*, 320, pp. 454-456.

Halliwell, B., 2001. Free Radicals and other reactive species in Disease, *Encyclopedia of Life Sciences*, [e-journal] Available at:<http://web.sls.hw.ac.uk/teaching/level4/bcm1_2/reading/oxidative_stress/files/Oxidative_stress.pdf> [Accessed 19 October 2013]

Huang, H., Patel, P. and Salahudeen, A., 2001. Lazaroid compounds prevent early but not late stages of oxidant-induced cell injury: potential explanation for the lack of efficacy of lazarooids in clinical trials, *Pharmacological Research*, 41(1), pp. 55-61.

Klinger, J., Abman, S. and Gladwin, M., 2013. Nitric Oxide Deficiency and Endothelial Dysfunction in Pulmonary Arterial Hypertension, *American Journal of Respiratory and Critical Care Medicine*, 188(6), pp. 639-646.

Lindemann, I., Boettcher, J., Oertel, K., Pasternack, R., Heine, A. and Klebe, G. 2012. Inhibitors of Transglutaminase 2: A therapeutic option in celiac disease, *To be Published*, [e-journal + PDB structure] Available at:<<http://www.ebi.ac.uk/pdbe-srv/view/entry/3s3s/summary>> [Accessed 24 October 2013]

Mayo Clinic, 2011. *Glomerulonephritis* [online] Available at: <<http://www.mayoclinic.com/health/glomerulonephritis/DS00503/>> [Accessed 20 October 2013].

McCord, J., Roy, R. and Schaffer, S., 1985. Free radicals and myocardial ischemia. The role of xanthine oxidase, *Advances in myocardiology*, [e-journal] Available at:<<http://www.ncbi.nlm.nih.gov/pubmed/2982206>> [Accessed 24 October 2013]

National Health Service, 2012. *Causes of glomerulonephritis* [online] Available at: <<http://www.nhs.uk/Conditions/Glomerulonephritis/Pages/Causes.aspx>> [Accessed 20 October 2013].

Niaudet, P., 2013. *Overview of the pathogenesis and causes of glomerulonephritis in children*. [online] Available at: <<http://www.uptodate.com/contents/overview-of-the-pathogenesis-and-causes-of-glomerulonephritis-in-children>> [Accessed 21 October 2013].

Ronco, P., 2013. *Mechanisms of glomerular crescent formation*. [online] Available at: <<http://www.uptodate.com/contents/mechanisms-of-glomerular-crescent-formation>> [Accessed 21 October 2013].

Rutchik, J., 2013. *Toxic Neuropathy Clinical Presentation*. [online] Available at: <<http://emedicine.medscape.com/article/1175276-clinical#a0216>> [Accessed 26 October 2013].

R&D Systems, 2013. *Technical Information. Ischemia/Reperfusion Injury*. [online] Available at: <http://www.rndsystems.com/cb_detail_objectname_SP96_Ischemia.aspx> [Accessed 28 October 2013].

Salahudeen, A., 1999. Free Radicals in Kidney Disease and Transplantation, *Saudi Journal of Kidney Diseases and Transplantation*, 10(2), pp. 137-143.

Sarma, A., Mallick, A. and Ghosh, A., 2010. Free Radicals and Their Role in Different Clinical Conditions: An Overview, *International Journal of Pharma Sciences and Research*, 1(3), pp. 182-192.

Shah, S., Baliga, R., Rajapurkar, M. and Fonseca, V., 2007. Oxidants in Chronic Kidney Disease, *Journal of the American Society of Nephrology*, 18(1), pp. 16-28.

The University of Utah, Unknown. *Glomerulonephritis* [online] Available at: <<http://library.med.utah.edu/WebPath/RENAHTML/RENALIDX.html#8>> [Accessed 25 October 2013].

Wang, C. and Salahudeen, A., 1994. Cyclosporine nephrotoxicity: attenuation by an antioxidant -inhibitor of lipid peroxidation in-vitro and in-vivo, *Transplantation*, 58, pp. 940-946.

Wang, C. and Salahudeen, A., 1995. Lipid peroxidation accompanies cyclosporine nephrotoxicity: effects of vitamin E, *Kidney International*, 47, pp. 927-934.

Weiss, S., 1989. Tissue Destruction by Neutrophils, *New England Journal of Medicine*, 320, pp. 365-376.